Patient Pure X (PPX™): Autologous EV Concentrate — 1 Source, Your Own Biology

Patient Pure X™ (PPX™) is an autologous extracellular vesicle concentrate derived from a patient's own blood through a specialized cGMP centrifugation process that isolates and concentrates platelet-derived extracellular vesicles beyond standard PRP preparation.

PPX™ occupies a specific niche in the biologic hierarchy at Rebuild Regen. It provides more than standard PRP by isolating the EV fraction — the nanoscale signaling particles within platelet-rich preparations — while maintaining the autologous character of the treatment. No donor tissue. No allogeneic exposure. Everything comes from your own blood.

This makes PPX™ particularly relevant for patients who want the signaling sophistication of exosome therapy but prefer to avoid allogeneic biologics, patients with contraindications to donor-derived products, or patients for whom autologous biologics are clinically preferred.

What PPX™ Is — Autologous EVs, Not Just PRP

Standard platelet-rich plasma therapy concentrates platelets and their growth factor payload. PPX™ takes that process further by specifically isolating the extracellular vesicle fraction within the platelet concentrate — the nanoscale EV particles that carry the molecular signaling payload (growth factors, micro-RNA, cytokines) that drives much of PRP's regenerative mechanism.

Research into platelet biology has clarified that a significant portion of PRP's paracrine effect is mediated not by platelets directly, but by the exosomes and microvesicles those platelets release upon activation. PPX™ concentrates that EV fraction through a specialized centrifugation protocol developed by ZEO ScientifiX that goes beyond standard single or double-spin PRP preparation.

The result is an autologous product with enhanced extracellular vesicle concentration, providing the molecular signaling benefits of EV therapy from the patient's own biological material. Because it's autologous, there is no rejection risk and no regulatory exposure from allogeneic product handling.

How PPX™ Differs From Standard PRP

The distinction is in the processing depth and the target fraction:

Standard PRP: Two-spin centrifugation isolating platelets and plasma, discarding red blood cells. Growth factors are released when platelets activate at the injection site. The cellular platelet fraction is the active component.

PPX™: Specialized multi-step centrifugation that isolates and concentrates the extracellular vesicle fraction from the platelet layer. The EV concentrate is separated from residual cellular components. What remains is a high-concentration autologous EV preparation designed for more targeted molecular delivery.

The clinical difference matters for applications where EV-mediated signaling is the primary mechanism of interest — joint inflammation modulation, follicle-level signaling for hair restoration, and tissue microenvironment repair in conditions where the growth factor signaling of standard PRP is insufficient.

Clinical Applications

PPX™ at Rebuild Regen is applied in several contexts:

Orthopedic injections: PPX™ is used as an upgrade from standard PRP for joint and soft tissue conditions where a more concentrated EV signal is clinically appropriate. This includes patients with moderate osteoarthritis, chronic tendinopathy, or conditions that have not responded fully to standard PRP.

Hair restoration: Scalp injection with PPX™ provides follicle-level EV signaling that targets the molecular pathways driving hair follicle activity. The EV fraction from platelet-derived sources includes growth factors (VEGF, PDGF, IGF-1) and micro-RNA sequences relevant to follicle cycling.

Combination protocols: PPX™ is often layered into combination biologic protocols as an autologous bridge between PRP and allogeneic exosomes. A patient receiving DayZero™ stem cells may receive PPX™ at the same site as a complementary autologous EV signal.

Aesthetic applications: Fine-line injection and skin rejuvenation protocols where an autologous EV signal supports cellular turnover and collagen synthesis.

The PPX™ Process at Rebuild Regen

PPX™ is prepared during the same clinic visit as treatment:

Blood draw (volume determined by protocol, typically 30 to 60 mL)
Multi-step centrifugation following the ZEO ScientifiX PPX™ protocol — this takes approximately 40 to 45 minutes
EV fraction isolation and preparation for injection
Same-session administration at the target site

Because the product is autologous and prepared on-site, PPX™ does not require the cold-chain storage or regulatory handling that allogeneic products require. For patients who travel for treatment, this simplicity is an advantage.

Session duration including preparation and injection is typically 60 to 90 minutes depending on the number of treatment sites.

Is PPX™ Right for Your Situation?

PPX™ is an appropriate option if you want autologous biologic therapy with enhanced EV concentration beyond standard PRP, if you have had a partial response to PRP and want to escalate within the autologous framework before moving to allogeneic products, or if your clinical picture suggests EV-mediated signaling is the mechanism most relevant to your condition.

Elizabeth reviews your history, any prior PRP or biologic experience, and your current clinical status to determine whether PPX™ alone, PPX™ combined with allogeneic products, or a different protocol is the right approach.

Frequently Asked Questions

Is PPX™ the same as PRP?

PPX™ and PRP both start from the patient's own blood and involve centrifugation. The difference is processing depth and target fraction. Standard PRP concentrates platelets. PPX™ concentrates the extracellular vesicle fraction from those platelets, providing a more refined molecular signaling preparation. PPX™ is a more advanced autologous biologic.

Does PPX™ use donor cells or materials?

No. PPX™ is fully autologous — derived entirely from the patient's own blood. There are no donor cells, allogeneic tissue, or foreign biological materials.

How is PPX™ different from DayZero™ exosomes?

DayZero™ exosomes are allogeneic — derived from perinatal donor tissue — and come in standardized high-concentration vials (150B to 500B particles). PPX™ is autologous — from the patient's own blood — with EV concentration that varies based on the patient's biology. Allogeneic exosomes typically provide a higher particle count and a more potent signaling payload. PPX™ is preferred when autologous sourcing is clinically or personally important to the patient.

How many PPX™ sessions are needed?

Most patients complete 2 to 3 sessions spaced 4 to 6 weeks apart for orthopedic or hair restoration applications. A single session is appropriate for certain aesthetic or combination protocols. Elizabeth determines the session plan based on the indication.

When PPX™ Is Not the Optimal Choice

PPX™ depends on the quality and EV content of the patient's own blood. In patients with platelet dysfunction, low platelet counts, or conditions that compromise blood quality, the PPX™ preparation may have reduced EV concentration and signaling potency. In these cases, allogeneic biologics such as DayZero™ stem cells or exosomes provide a more reliable and potent EV payload. For advanced conditions requiring the highest available paracrine signaling effect, allogeneic products are typically the stronger clinical choice. Elizabeth evaluates this honestly and recommends accordingly.

Rebuild Regen Medical Clinic 3320 N Federal Hwy #101, Lighthouse Point, FL 33064 (954) 953-4208 | rebuildregenmedical.com

Schedule a Consultation | Compare PRP, PPX™, and Exosome Therapy